2-丁基吡嗪 | 29460-91-1

• 物质功能分类: 香精与香料 - 合成香料 - 吡嗪类香料
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-丁基吡嗪
• 英文名称: 2-butylpyrazine
• CAS: 29460-91-1
• 化学式: C₈H₁₂N₂
• mdl: MFCD08457819
• 分子量: 136.197
• InChiKey: TVAVRPSANVGCNH-UHFFFAOYSA-N

物化性质

• 沸点：
  84 °C(Press: 19 Torr)
• 密度：
  0.961±0.06 g/cm3(Predicted)
• LogP：
  1.871 (est)
• 保留指数：
  1088;1088

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-丁基吡嗪 在 氢溴酸 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 RP132
  参考文献：
  名称：

  Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects

  摘要：

  Cyclin-dependent kinases (CDKs) regulate the cell cycle, apoptosis, neuronal functions, transcription, and exocytosis. The observation of CDK deregulations in various pathological situations suggests that CDK inhibitors may have a therapeutic value. In this article, we report on the identification of 6-phenyl[5H]pyrrolo[2,3-b]pyrazines (aloisines) as a novel potent CDK inhibitory scaffold. A selectivity study performed on 26 kinases shows that aloisine A is highly selective for CDK1/cyclin B, CDK2/cyclin A-E, CDK5/p25, and GSK-3alpha/beta; the two latter enzymes have been implicated in Alzheimer's disease. Kinetic studies, as well as the resolution of a CDK2-aloisine cocrystal structure, demonstrate that aloisines act by competitive inhibition of ATP binding to the catalytic subunit of the kinase. As observed with all inhibitors reported so far, aloisine interacts with the ATP-binding pocket through two hydrogen bonds with backbone nitrogen and oxygen atoms of Leu 83. Aloisine inhibits cell proliferation by arresting cells in both G1 and G2.

  DOI：

  10.1021/jm020319p
• 作为产物：
  描述：

  n-Butyl 2-pyrazinyl-sulfon 以42%的产率得到
  参考文献：
  名称：

  KONAKAHARA T.; GOKAN K.; IWAMA M.; TAKAGI Y., HETEROCYCLES, 1979, 12, NO 3, 373-376

  摘要：

  DOI：

文献信息

• COVALENTLY ATTACHED ANTIMICROBIAL POLYMERS
  申请人：Steinberg Thorsten

  公开号：US20130338326A1

  公开（公告）日：2013-12-19

  The present invention relates to substrates comprising covalently attached antimicrobial polymers, which act as synthetic mimics of antimicrobial peptides (SMAMPs) and are preferably obtained by ring opening metathesis polymerization (ROMP). The inventive antimicrobial polymers exhibit a molecular weight of more than 100,000 g mol −1 and are preferably covalently attached to the surface of a substrate, e.g. an implant, a medical device, medical equipment or a (tissue-supporting) biomaterial, etc. Covalent bonding may be carried out using a photoreactive crosslinker but also by “grafting onto” or “grafting from”. The present invention is also directed to uses of the inventive antimicrobial polymers as defined herein, e.g. for antimicrobially coating a surface of such a substrate with a layer of the inventive antimicrobial polymer.

  本发明涉及包含共价连接的抗菌聚合物的基板，这些聚合物作为抗菌肽（SMAMPs）的合成模拟体，并且最好是通过环烯烃开环甲基交换聚合（ROMP）获得的。这种创新的抗菌聚合物的分子量超过100,000克/摩尔，并且最好是共价连接到基板表面上，例如植入物、医疗器械、医疗设备或（支持组织的）生物材料等。共价键合可以使用光反应性交联剂进行，也可以通过“接枝到”或“接枝自”来进行。本发明还涉及如上所定义的创新抗菌聚合物的用途，例如，用创新抗菌聚合物的层对这种基板的表面进行抗菌涂层。
• Manganese-Catalyzed Kumada Cross-Coupling Reactions of Aliphatic Grignard Reagents with N-Heterocyclic Chlorides
  作者：Ellen Matson、Brittney Petel、Merjema Purak

  DOI：10.1055/s-0037-1610200

  日期：2018.8

  manganese(II) chloride for the catalytic generation of C(sp2)–C(sp3) bonds via Kumada cross-coupling. Rapid and selective formation of 2-alkylated N-heterocyclic complexes were observed in high yields with use of 3 mol% MnCl2THF1.6 and under ambient reaction conditions (21 °C, 15 min to 20 h). Manganese-catalyzed cross-coupling is tolerant toward both electron-donating and electron-withdrawing functional

  在此，我们报告了使用氯化锰 (II) 通过 Kumada 交叉偶联催化生成 C(sp2)–C(sp3) 键。在使用 3 mol% MnCl2THF1.6 和环境反应条件（21 °C，15 分钟至 20 小时）下，观察到 2-烷基化 N-杂环配合物的快速和选择性形成。锰催化的交叉偶联对吡啶环 5 位的给电子和吸电子官能团都具有耐受性，后者导致反应速率增加和所需亲核试剂的量减少。使用这种对生物和环境无害的金属盐作为 C-C 键形成的催化剂，突出了其作为药学活性 N-杂环分子（例如吡啶、吡嗪）后期功能化催化剂的潜力。
• Monoquaternized pyrazinium compounds and their use as electron carriers
  申请人：The Coca-Cola Company

  公开号：US04638005A1

  公开（公告）日：1987-01-20

  Substituted pyrazinium compounds having at least one polar group such as hydroxyl, carboxyl, carbamido or sulfonoxy can act as high energy electron carriers in photosynthetic processes such as those employing chlorophyll and a reduction enzyme. Such processes with the pyrazinium compounds can produce ammonia and hydrogen.

  含有至少一个极性基团（如羟基、羧基、氨基或磺氧基）的取代吡啶化合物可以在光合作用过程中充当高能电子载体，例如那些使用叶绿素和还原酶的过程。这些含有吡啶化合物的过程可以产生氨和氢。
• [EN] 3,4-DIAMINOBENZENESULFONAMIDE DERIVATIVES FOR INHIBITING CELL DEATH<br/>[FR] DÉRIVÉS DE 3,4-DIAMINOBENZÈNESULFONAMIDE POUR INHIBER LA MORT CELLULAIRE
  申请人：VIB VZW

  公开号：WO2016075330A1

  公开（公告）日：2016-05-19

  The present invention relates to a novel class of compounds having the structure of formula (I) and pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof. These compounds inhibit or reduce the non-apoptotic cell death forms ferroptosis and/or oxytosis rendering them useful for the treatment of various conditions disclosed herein.

  本发明涉及一种新型化合物类，其结构式为(I)，以及包含式(I)化合物或其药学上可接受的盐的制药组合物。这些化合物抑制或减少非凋亡细胞死亡形式的铁死亡和/或氧死亡，因此可用于治疗本文所披露的各种疾病。
• HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS
  申请人：Morriello Gregori J.

  公开号：US20100069347A1

  公开（公告）日：2010-03-18

  This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts thereof, wherein R 12 is a hydroxylated alkyl group and R 9 contains a heterocyclic ring. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating atherosclerosis and preventing atherosclerotic disease events.

  本发明提供了I式胆固醇吸收抑制剂及其药学上可接受的盐，其中R12是一个羟基化的烷基基团，而R9包含一个杂环环。这些化合物对降低血浆胆固醇水平，特别是低密度脂蛋白胆固醇，以及治疗动脉粥样硬化和预防动脉粥样硬化疾病事件具有用处。